Kanghuai Zhang
Overview
Explore the profile of Kanghuai Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Qu K, Li X, Yang X, Zhang K, Xie J
Front Immunol
. 2025 Feb;
16:1505195.
PMID: 39958361
This case report presents a 57-year-old male with hepatocellular carcinoma who developed Type 1 Diabetes Mellitus (T1DM) and diabetic ketoacidosis (DKA) following treatment with Envafolimab, a PD-L1 immune checkpoint inhibitor....
2.
Zhao Y, Li Z, Zhang K, Wang N
Expert Opin Drug Saf
. 2024 Dec;
:1-7.
PMID: 39711190
Background: Ustekinumab is a fully human interleukin-12/23 (p40) inhibitor used to treat immune-mediated diseases. However, the limitations of clinical trials and the expanding target population necessitate an update on the...
3.
He F, Sun Y, Zhang W, Wu Q, Xu D, Bai Z, et al.
Discov Oncol
. 2024 Nov;
15(1):712.
PMID: 39589666
Objective: This study aimed to assess the safety and efficacy of generic nab-paclitaxel in the Chinese population in a real-world setting. Methods: This prospective, multicenter, observational study enrolled patients with...
4.
Liu Y, Dai M, Zhang K, Zhang L, Lin B, Chen K, et al.
Int J Antimicrob Agents
. 2024 Aug;
64(4):107288.
PMID: 39089342
Objective: Antibiotic utilization stands as the strongest modifiable determinant for Clostridioides difficile infection (CDI). However, previous studies have relied on aggregated antibiotic categories, leaving prescribers without detailed comparative risk information...
5.
Zhao Y, Li Z, Zhang K, Wang N
Expert Opin Drug Saf
. 2024 May;
23(8):1041-1048.
PMID: 38769926
Background: Tumor necrosis factor-α inhibitors (TNFis) are used for the treatment of inflammatory bowel disease (IBD). The aim of this study was to evaluate the association between neurological adverse events...
6.
Zhao Y, Zhang Y, Yang L, Zhang K, Li S
Ann Pharmacother
. 2024 Feb;
58(11):1105-1116.
PMID: 38407147
Background: Selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed agents to treat depression. Considering the growth in antidepressant prescription rates, SSRI-induced adverse events (AEs) need to be comprehensively...
7.
Xiang C, Li S, Zhang J, Zhang J, Hu S, Pan M, et al.
Front Pharmacol
. 2023 Apr;
14:1079972.
PMID: 37007018
Oxycodone/acetaminophen has been reported for misuse for many times in China. To cope with that, Chinese national authorities jointly issued a policy, requiring that oxycodone/acetaminophen should be managed as a...
8.
Yang Q, Xie J, Cai Y, Wang N, Wang Y, Zhang L, et al.
Infect Drug Resist
. 2022 Sep;
15:5331-5344.
PMID: 36110125
Purpose: To determine whether combinations of antifungal drugs are effective and safe for patients in intensive-care units. Methods: This study compared the efficacy and safety of caspofungin (CAS), voriconazole (VOR),...
9.
Yang Q, Liu Z, Wang Y, Xie J, Zhang K, Dong Y, et al.
Int J Infect Dis
. 2022 Jul;
122:982-990.
PMID: 35907476
Objectives: Increased resistance of Candida species, especially Candida. glabrata is problematic. Combination antifungal therapies were studied to solve the problem. Methods: In this study, combinations of caspofungin with fluconazole and...
10.
Cai Y, Zhang M, Wang Y, Wang N, Zhang L, Zhang K
J Clin Pharm Ther
. 2021 Jun;
46(5):1382-1386.
PMID: 34114239
What Is Known And Objective: To observe the effect of latamoxef on coagulation function and to analyse its risk factors. Methods: A retrospective cohort study was performed to compare patients...